神经节苷脂联合依达拉奉治疗颈内动脉系统大面积脑梗死的疗效分析  

To explore the therapeutic effects of ganglioside GM-1 and edaravom for severe cerebral infarction

作　　者：赖春凤[1] 伍苏方[2] 

机构地区：[1]嘉应学院医学院附属医院内科,梅州514031 [2]湖南省永州市人民医院神经内科,423000

出　　处：《中国医疗前沿》2010年第8期48-49,共2页China Healthcare Innovation

摘　　要：目的探讨神经节苷脂联合依达拉奉治疗大面积脑梗死的临床疗效。方法将发病48h内的大面积脑梗死的病人74例,随机分入治疗组和对照组。对照组应用神经节苷脂注射液60mg静脉滴注,1次/d,共21d,同时给予阿司匹林、低分子肝素作为基础治疗;治疗组应用神经节苷脂注射液60mg,1次/d,同时给予依达拉奉注射液30mg静脉滴注,2次/d,共21d。发病72h和治疗后定期对患者行欧洲卒中评分(ESS)、日常生活活动能力(ADL)评分,以治疗21dESS的评分和第90d的ADL评分作为主要疗效判断标准。结果21d后联合治疗组和对照组的ESS评分分别为(67.32±15.36)、(50.21±13.04),两组相比差异有显著性(p<0.01);90d后治疗组、对照组ADL(改良Barthel指数)评分分别为(75.38±20.56)、(54.63±28.59),两组相比有差异有显著性(p<0.01)。结论神经节苷脂联合依达拉奉治疗大面积脑梗死疗效明显。Objective Purpose To explore the therapeutic effects of of ganglioside GM-1 and edaravone for severe cerebral infarction. Methods 74 patients with severe cerebral infarcdon within 48 hours after the onset of stroke symptom were randomly assigned to receive ganglioside GM-1 and edaravone （n=38） or ganglioside GM-1 （control group,n=36）. Ganglioside GM-1 and edaravone were infused at a dose of 60mg per day or 30mg twice a day,respectively,for 21 days. Meanwhile aspirin and low-molecular-weight heparin were used as basic treatment.72h after onset and 21 days and 3 months after treatment,the neurological deficits were evaluated with the use of European Stroke Scale （ESS） and activities of daily living （ADL）. Results There were significant differences in ESS between GM-1 group and control group at 21 day （67.32±15.36 Vs.50.21±13.04,p〈 0.01）. There were also significant differences in ADL at 90 day between the groups （75.38±20.56 Vs 54.63±28.59,p〈 0.01）. Conclusion Ganglioside GM-1 and edaravone has a goodtherapeutic effect for severe cerebral infarction.

关 键 词：神经节苷脂 依达拉奉 脑梗死 

分 类 号：R743.33[医药卫生—神经病学与精神病学]